Comparative Pharmacology
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus ESTROVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus ESTROVIS.
DESOGESTREL AND ETHINYL ESTRADIOL vs ESTROVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Estrovis (estropipate) acts by binding to estrogen receptors (ERα and ERβ), leading to activation of estrogen-responsive genes. It increases hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins, and suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
One tablet (0.15 mg desogestrel/0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo tablets, then repeat cycle.
1 mg orally once daily, continuous dosing cycle (no placebo week).
None Documented
None Documented
Desogestrel: terminal half-life 23-27 hours (active metabolite etonogestrel); clinically allows once-daily dosing. Ethinyl estradiol: terminal half-life 12-15 hours (range 10-20 hours) with biphasic elimination; supports daily administration.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 3-5 days.
Desogestrel: primarily renal (approximately 60% as metabolites), 30% fecal. Ethinyl estradiol: primarily renal (approximately 40% as glucuronide conjugates), 60% fecal.
Renal: 60-70% as glucuronide and sulfate conjugates; Fecal/biliary: 20-30% as conjugated metabolites.
Category D/X
Category C
Estrogen
Estrogen